Abstract
The objective of this study was to investigate the effects of autologous neurogenically induced bone marrow-derived mesenchymal stem cells (NIBM-MSCs) in two dogs suspected to have fibrocartilaginous embolic myelopathy (FCEM). Both dogs were paraplegic without deep pain perception (DPP) and tentatively diagnosed by MRI. Autologous NIBM-MSCs (5 × 106) were transplanted into the lumbar subarachnoid space two times with a 21-day interval for each patient. Based on a 21-month follow-up of the treated animals, the transplantation of NIBM-MSCs seems to be promising in subjects with FCEM lacking DPP.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
